Book a Demo | Airfinity

Obesity Newsletter Latest

TBC

<!doctype html><html> <head> <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"> <meta name="viewport" content="width=device-width, initialscale=1.0"> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <style type="text/css">@media screen and (max-width: 480px) {slot[style] {margin-right: 0 !important;}.columnDiv {margin-right: 0 !important;}}@media screen and (min-width: 480px) {slot[style] {margin-bottom: 0 !important;}.columnDiv {margin-bottom: 0 !important;}}</style> <style type="text/css">.contentpageDefaultEmailContentPageTemplate .contentRoot {width: 600px;}@media only screen and (max-width: 480px) {.contentpageDefaultEmailContentPageTemplate .contentRoot {width: 320px;}}</style> <style type="text/css">@media screen and (max-width: 480px) {.contentbuilderBaseColumnRow .columnCell {display:inline-block;width:100%}}</style> </head> <body> <table class="contentpageDefaultEmailContentPageTemplate" style="background-color: #E9EAEC;" role="presentation" id="contentpage_emailContentBodyContent" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr> <td width="100%" align="center"> <table class="contentRoot" role="presentation" width="600" cellpadding="0" cellspacing="0" bgcolor="#FFFFFF"> <tbody> <tr> <td style="padding-top: 10px; padding-bottom: 10px; padding-left: 10px; padding-right: 10px;"> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><a href="https://go.airfinity.com/e/936853/2023-12-01/7r8s1/230032428/h/36skm1JSzUnWnucAQIHUAnsskN7GDb02HSbqZHE023g" target="_blank"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCWWS3O27P3VGRJA4VLNTMCE5BAU?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></a></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;">1 December 2023</td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><p><span style="line-height:1.5;"><span style="font-size:14px;"><i><span style="color:#575756;"><span style="font-family:Arial,Helvetica,sans-serif;">Interested in more in-depth forecasts and intelligence on the link between obesity and specific CVRM outcomes? Reach out to </span></span></i></span></span><a href="mailto:cardiovascular@airfinity.com"><span style="line-height:1.5;"><span style="font-size:14px;"><i><span style="color:#575756;"><span style="font-family:Arial,Helvetica,sans-serif;"><u>cardiovascular@airfinity.com</u></span></span></i></span></span></a></p><p><span style="display: none;"> </span></p></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="padding-top: 10px;" align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MC4MKF4LK7ZBAFHI47EQHISYRLJI?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><span style="font-size:20px;"><b>Summary</b></span></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="padding-top: 10px;" align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MC4MKF4LK7ZBAFHI47EQHISYRLJI?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><span style="line-height:1.5;"><font face="Arial, Helvetica, sans-serif"><i>This week, Novo Nordisk announced a flexible pricing strategy to help expedite access and uptake of <u><strong>Wegovy</strong></u> to healthcare providers. Nevertheless, the list price and current out-of-pocket expenses are still higher than competing <u><strong>tirzepatide (Zepbound)</strong></u> in the US. <u><strong>Tirzepatide</strong></u> has also demonstrated superiority to <u><strong>semaglutide</strong></u> in a preprint, with real-world evidence demonstrating almost twice as much weight loss with <u><strong>tirzepatide</strong></u> compared to <u><strong>semaglutide</strong></u> in patients living with obesity in the US. This is in line with the indirect differences seen through clinical trial comparisons and Airfinity’s previous analysis, and may sway patient preference. A separate study has revealed the potential efficacy of these drugs to treat alcohol use disorder in a patient-reported US study. Outside of top two obesity market contenders, Pfizer announced discontinuation of their twice-daily approach with Phase II oral GLP-1 receptor agonist, <u><strong>danuglipron</strong></u>, due to poor safety signals. This had an immediate impact, reducing Pfizer’s stock value by 4%. Pfizer has now reverted to Phase I trials with a once-daily regimen with <u><strong>danuglipron</strong></u>. Finally, five obesity bodies have urged the FDA to ensure inclusion of patients with obesity in clinical trials, as many trials have BMI cut-offs to exclude these patients, to minimise confounding risk factors.</i></font></span><p><span style="display: none;"> </span></p></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="padding-top: 10px;" align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MC4MKF4LK7ZBAFHI47EQHISYRLJI?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><span style="font-size:20px;"><b>Analysis</b></span></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="padding-bottom: 10px;" align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MC4MKF4LK7ZBAFHI47EQHISYRLJI?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:#FFED00;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><strong><span style="font-size:14px;"><em><span style="line-height:1.5;">Regulatory Update</span></em></span></strong></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="padding-right: 5px;padding-bottom: 5px;padding-left: 5px;" align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCDBDGZX3IMBHWHPXWZKLNTNVGJQ?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="590"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 20px;padding-bottom: 10px;padding-left: 10px;"> <div style="text-align: right;"> <em>Source: </em><a href="https://go.airfinity.com/e/936853/tement-drug-approval-labeling-/7r8s4/230032428/h/36skm1JSzUnWnucAQIHUAnsskN7GDb02HSbqZHE023g"><span style="color:#000000;"><em><u>Obesity Action Coalition</u></em></span></a> </div></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCOUVWBW35LJFN3MMNDPP7NJPLUU?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:#A8A8A8;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><strong><span style="font-size:14px;"><em><span style="line-height:1.5;">Commercial Update</span></em></span></strong></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="padding-right: 5px;padding-left: 5px;" align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCECUEIRZC4VGB7B4YC4DJDRN35A?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="590"></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="padding-right: 5px;padding-bottom: 5px;padding-left: 5px;" align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCZXW2KF45W5DXXDTGMFRWXQ5YTM?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="590"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 20px;padding-bottom: 10px;padding-left: 10px;"> <div style="text-align: right;"> <em>Source: </em><a href="https://go.airfinity.com/e/936853/fe-fcca-450f-89cc-f986553eb6db/7r8s7/230032428/h/36skm1JSzUnWnucAQIHUAnsskN7GDb02HSbqZHE023g"><span style="color:#000000;"><em><u>Financial Times</u></em></span></a> </div></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCOUVWBW35LJFN3MMNDPP7NJPLUU?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:#000000;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><strong><span style="color:#ffffff;"><span style="font-size:14px;"><em><span style="line-height:1.5;">Clinical Update</span></em></span></span></strong></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="padding-right: 5px;padding-left: 5px;" align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCVOHNKIQ2TBBEJHBTSXZVIUZRAY?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="590"></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="padding-right: 5px;padding-bottom: 5px;padding-left: 5px;" align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCW4S4ZDYHWNDIFIEM4HL6665VD4?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="590"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 20px;padding-bottom: 10px;padding-left: 10px;"> <div style="text-align: right;"> <span style="line-height:1.5;"><em>Source: </em></span><a href="https://go.airfinity.com/e/936853/101-2023-11-21-23298775v1-full/7r8sb/230032428/h/36skm1JSzUnWnucAQIHUAnsskN7GDb02HSbqZHE023g"><span style="color:#000000;"><span style="line-height:1.5;"><em><u>Rodriguez et al., 2023</u></em></span></span></a> </div></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCOUVWBW35LJFN3MMNDPP7NJPLUU?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:#AAAAAA;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><span style="color:#000000;"><strong><span style="font-size:14px;"><em><span style="line-height:1.5;">Disease Outcomes Update</span></em></span></strong></span></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="padding-right: 5px;padding-bottom: 5px;padding-left: 5px;" align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MC5I6ASOPDBNEBVCMXHP743P7UXA?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="590"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 20px;padding-bottom: 10px;padding-left: 10px;"> <div style="text-align: right;"> <span style="line-height:1.5;"><em>Source: </em></span><a href="https://go.airfinity.com/e/936853/articles-s41598-023-48267-2/7r8sf/230032428/h/36skm1JSzUnWnucAQIHUAnsskN7GDb02HSbqZHE023g"><span style="color:#000000;"><u><span style="line-height:1.5;"><em>Quddos et al., 2023</em></span></u></span></a> </div></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCOUVWBW35LJFN3MMNDPP7NJPLUU?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="padding-top: 10px;" align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MC4MKF4LK7ZBAFHI47EQHISYRLJI?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><span style="font-size:20px;"><b>Current Pipeline</b></span></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="padding-top: 10px;" align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MC4MKF4LK7ZBAFHI47EQHISYRLJI?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><p><span style="font-size:16px;"><span style="line-height:1.5;"><b>Airfinity have added 7 new anti-obesity candidates to the pipeline tracker this week</b></span></span></p></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCFKTNNIKUKNBRJCH5ZAKBVTEJQY?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><p><em><span style="line-height:1.5;">This week, Airfinity has identified 7 new anti-obesity candidates, bringing the total number of tracked candidates to 187, from pre-clinical through to post-approval. Novo Nordisk announced their Phase III SUSTAIN OPTIMIZE (NCT05514535) trial examining glycaemic and weight loss outcomes of patients administered semaglutide with low and higher doses of insulin glargine in patients with type 2 diabetes. Airfinity has also identified three candidates involved in trials from non-pharma organisations. These include a study examining the effects of brain stimulation on food intake drive and weight loss (NCT00739362), another examining the capacity of metformin to transport metformin into the cerebrospinal fluid in patients with obesity (NCT03974139), and finally a trial examining the weight loss capacity of the SGLT2i, empagliflozin (NCT05885074).<br><br> Regeneron published the preclinical and Phase I trial results of their anti-obesity candidate, mibavademab (REGN4461) - a leptin receptor agonist. This drug demonstrated up to 3.1% weight loss during an 85 day treatment period in patients with overweight/obesity and low leptin levels. Airfinity also added Gubra’s Phase I asset, GUB014295, a long-acting amylin receptor analogue (NCT06144684) and the probiotic Bifidobacterium Longum BL21 (NCT06140641).</span></em></p></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCOWBGIQAXEJAD5HXUA6V5F44D4Y?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><p><span style="font-size:16px;"><span style="line-height:1.5;"><b>Airfinity is now tracking a total of 187 anti-obesity candidates<br> from pre-clinical through to post-approval</b></span></span></p></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 90%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCLU654G7IVBDODHTUOXL2G4BWRM?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="540"></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCOWBGIQAXEJAD5HXUA6V5F44D4Y?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><p><span style="font-size:16px;"><span style="line-height:1.5;"><b>GLP-1 receptor agonists are the most common drug class in late stage clinical trials</b></span></span></p></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 95%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCSPTYCXNIIFHBZKY6MDJIURCUFY?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="570"></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCOWBGIQAXEJAD5HXUA6V5F44D4Y?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><p><span style="font-size:16px;"><span style="line-height:1.5;"><b>Early pipeline candidates demonstrate a focus shift towards co-GLP-1 receptor agonists, including targeting of amylin and peptide YY</b></span></span></p></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 95%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCGJK62E3K2FFWHGKK2M6WQXF6R4?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="570"></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCOWBGIQAXEJAD5HXUA6V5F44D4Y?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><p><span style="font-size:16px;"><span style="line-height:1.5;"><b>Early pipeline candidates demonstrate a focus shift towards co-GLP-1 receptor agonists, including targeting of amylin and peptide YY</b></span></span></p></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><p><em><span style="line-height:1.5;">Trials reaching completion by the end of the year include 6 Phase I trials, the first of which to reach primary completion is Shionogi’s trial of undisclosed asset S-309309 co-administered with itraconazole in healthy participants. Other notable Phase I trials reaching primary completion include: AstraZeneca’s trial of amylin receptor agonist, AZD6234; Novo Nordisk’s trial of dual amylin/GLP-1 receptor agonist, amycretin; and Boehringer Ingelheim’s dose finding and tolerability study of survodutide (GLP-1R/GCG-R dual agonist) in adults with obesity and with and without liver dysfunction. There is one Phase II trial reaching completion in December 2023. This is for Structure Therapeutics’ drug, GSBR-1290, which is one of 14 small molecule oral GLP-1 receptor agonists in the pipeline. Later stage assets reaching completion are largely of older approved drugs, such as a trial examining the impact of the GLP-1 receptor agonist liraglutide on epicardial adipose tissue.</span></em></p></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCOWBGIQAXEJAD5HXUA6V5F44D4Y?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><p><span style="font-size:16px;"><span style="line-height:1.5;"><b>Items of Interest</b></span></span></p></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><p><em><span style="line-height:1.5;">This past week </span></em><a href="https://go.airfinity.com/e/936853/toc-stm-current/7r8sj/230032428/h/36skm1JSzUnWnucAQIHUAnsskN7GDb02HSbqZHE023g"><em><span style="line-height:1.5;">Science Translational Medicine</span></em></a><em><span style="line-height:1.5;"> released a special issue focussed on obesity, comprising several viewpoints, reviews and primary research articles.</span></em></p></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="padding-top: 15px;" align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MC4MKF4LK7ZBAFHI47EQHISYRLJI?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><span style="font-size:20px;"><b>News Overview</b></span></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="padding-top: 10px;" align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MC4MKF4LK7ZBAFHI47EQHISYRLJI?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><p><span style="line-height:1.5;"><b>Pfizer abandons twice-daily GLP-1 approach due to high discontinuation rates, goes back to PhI with once-a-day dose</b></span><br><span style="line-height:1.5;"><b><span style="color:#7f8c8d;"><i>Endpoints News- 1 December 2023</i></span></b></span><br><br><span style="line-height:1.5;">Pfizer won’t be moving a twice-daily formulation of its oral GLP-1, danuglipron, into Phase III after the drug triggered high rates of side effects, despite meeting the primary endpoint of its mid-stage weight loss trial.</span></p></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="border: 0; width: 100%; border-collapse: collapse; mso-table-lspace:0pt;mso-table-rspace:0pt;" locked="0"> <tbody> <tr> <td style="padding-right: 10px;padding-left: 10px;mso-table-lspace:0pt;mso-table-rspace:0pt;"> <div style="word-break:break-word; border: 0; mso-border-alt: 0; text-align:left; "> <div style="display: inline-block; border: 0; mso-border-alt: 0; "> <a style="direction:ltr;display:block;text-align:center;margin:0; font-family:Arial, Helvetica, sans-serif; font-size:12px; padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px; color:#000000;font-weight:normal;font-style:normal;text-decoration:none;border-width:2px;border-style:solid;border-color:#000000;background-color:#FFFFFF;border-radius:0px;mso-padding-alt:0;" href="https://go.airfinity.com/e/936853/uation-rates-goes-back-to-phi-/7r8sq/230032428/h/36skm1JSzUnWnucAQIHUAnsskN7GDb02HSbqZHE023g" target="_blank"><span>Read More →</span></a> </div> </div></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCOWBGIQAXEJAD5HXUA6V5F44D4Y?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><p><span style="line-height:1.5;"><b>Users of diabetes drug Mounjaro lost more weight than those on Ozempic, large study finds</b></span><br><span style="line-height:1.5;"><b><span style="color:#7f8c8d;"><i>CNN News - 28 November 2023</i></span></b></span><br><br><span style="line-height:1.5;">Overweight and obese adults who took the injected medication Mounjaro lost more weight and were more likely to meet specific weight loss targets than people on a similar competitor, Ozempic, according to a new study of people taking the drugs in the real world.</span></p></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="border: 0; width: 100%; border-collapse: collapse; mso-table-lspace:0pt;mso-table-rspace:0pt;" locked="0"> <tbody> <tr> <td style="padding-right: 10px;padding-left: 10px;mso-table-lspace:0pt;mso-table-rspace:0pt;"> <div style="word-break:break-word; border: 0; mso-border-alt: 0; text-align:left; "> <div style="display: inline-block; border: 0; mso-border-alt: 0; "> <a style="direction:ltr;display:block;text-align:center;margin:0; font-family:Arial, Helvetica, sans-serif; font-size:12px; padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px; color:#000000;font-weight:normal;font-style:normal;text-decoration:none;border-width:2px;border-style:solid;border-color:#000000;background-color:#FFFFFF;border-radius:0px;mso-padding-alt:0;" href="https://go.airfinity.com/e/936853/c-weight-loss-study-index-html/7r8st/230032428/h/36skm1JSzUnWnucAQIHUAnsskN7GDb02HSbqZHE023g" target="_blank"><span>Read More →</span></a> </div> </div></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCOWBGIQAXEJAD5HXUA6V5F44D4Y?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><p><span style="line-height:1.5;"><b>Bloomberg Intelligence sees key patent case protecting Novo Nordisk's USD 98bn Wegovy sale<br><span style="color:#7f8c8d;"><i>MedWatch - 29 November 2023</i></span></b></span><br><br><span style="line-height:1.5;">Bloomberg Intelligence estimates that Novo Nordisk’s patent case against American Mylan could keep a copy of obesity drug Wegovy at bay until 2038, which would ”protect” USD 98bn in revenue.</span></p></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="border: 0; width: 100%; border-collapse: collapse; mso-table-lspace:0pt;mso-table-rspace:0pt;" locked="0"> <tbody> <tr> <td style="padding-right: 10px;padding-left: 10px;mso-table-lspace:0pt;mso-table-rspace:0pt;"> <div style="word-break:break-word; border: 0; mso-border-alt: 0; text-align:left; "> <div style="display: inline-block; border: 0; mso-border-alt: 0; "> <a style="direction:ltr;display:block;text-align:center;margin:0; font-family:Arial, Helvetica, sans-serif; font-size:12px; padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px; color:#000000;font-weight:normal;font-style:normal;text-decoration:none;border-width:2px;border-style:solid;border-color:#000000;background-color:#FFFFFF;border-radius:0px;mso-padding-alt:0;" href="https://go.airfinity.com/e/936853/---Biotech-article16645168-ece/7r8sx/230032428/h/36skm1JSzUnWnucAQIHUAnsskN7GDb02HSbqZHE023g" target="_blank"><span>Read More →</span></a> </div> </div></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCOWBGIQAXEJAD5HXUA6V5F44D4Y?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><p><span style="line-height:1.5;"><b>Brain imaging identifies satiety signaling pathway with potential to improve weight loss drugs’ efficacy<br><span style="color:#7f8c8d;"><i>Reuters - 28 November 2023</i></span></b><br><br> Novel brain imaging shows brain cells signal the body to stop eating in response to the taste of food sent from the mouth rather than the fullness of the stomach.</span></p></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="border: 0; width: 100%; border-collapse: collapse; mso-table-lspace:0pt;mso-table-rspace:0pt;" locked="0"> <tbody> <tr> <td style="padding-right: 10px;padding-left: 10px;mso-table-lspace:0pt;mso-table-rspace:0pt;"> <div style="word-break:break-word; border: 0; mso-border-alt: 0; text-align:left; "> <div style="display: inline-block; border: 0; mso-border-alt: 0; "> <a style="direction:ltr;display:block;text-align:center;margin:0; font-family:Arial, Helvetica, sans-serif; font-size:12px; padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px; color:#000000;font-weight:normal;font-style:normal;text-decoration:none;border-width:2px;border-style:solid;border-color:#000000;background-color:#FFFFFF;border-radius:0px;mso-padding-alt:0;" href="https://go.airfinity.com/e/936853/eight-loss-drugs-efficacy-html/7r8t1/230032428/h/36skm1JSzUnWnucAQIHUAnsskN7GDb02HSbqZHE023g" target="_blank"><span>Read More →</span></a> </div> </div></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCOWBGIQAXEJAD5HXUA6V5F44D4Y?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><p><span style="line-height:1.5;"><b>Weight loss drug maker plots ‘buy now, pay later’ offer</b></span><br><span style="line-height:1.5;"><b><span style="color:#7f8c8d;"><i>The Telegraph - 27 November 2023</i></span></b></span><br><br><span style="line-height:1.5;">Novo Nordisk aims to treat more people who currently cannot access its Wegovy jabs.</span></p></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="border: 0; width: 100%; border-collapse: collapse; mso-table-lspace:0pt;mso-table-rspace:0pt;" locked="0"> <tbody> <tr> <td style="padding-right: 10px;padding-left: 10px;mso-table-lspace:0pt;mso-table-rspace:0pt;"> <div style="word-break:break-word; border: 0; mso-border-alt: 0; text-align:left; "> <div style="display: inline-block; border: 0; mso-border-alt: 0; "> <a style="direction:ltr;display:block;text-align:center;margin:0; font-family:Arial, Helvetica, sans-serif; font-size:12px; padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px; color:#000000;font-weight:normal;font-style:normal;text-decoration:none;border-width:2px;border-style:solid;border-color:#000000;background-color:#FFFFFF;border-radius:0px;mso-padding-alt:0;" href="https://go.airfinity.com/e/936853/plots-buy-now-pay-later-offer-/7r8t4/230032428/h/36skm1JSzUnWnucAQIHUAnsskN7GDb02HSbqZHE023g" target="_blank"><span>Read More →</span></a> </div> </div></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCOWBGIQAXEJAD5HXUA6V5F44D4Y?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><p><span style="line-height:1.5;"><b>Lilly's Weight-Loss Drug Wallops Novo's In Head-To-Head Study; Novo Stock Dives</b></span><br><span style="line-height:1.5;"><b><span style="color:#7f8c8d;"><i>Investors - 28 November 2023</i></span></b></span><br><br><span style="line-height:1.5;">Novo Nordisk (NVO) stock skidded Tuesday after Eli Lilly's (LLY) weight-loss drug outperformed Novo's rival medication in a first-of-its-kind study.</span></p></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="border: 0; width: 100%; border-collapse: collapse; mso-table-lspace:0pt;mso-table-rspace:0pt;" locked="0"> <tbody> <tr> <td style="padding-right: 10px;padding-left: 10px;mso-table-lspace:0pt;mso-table-rspace:0pt;"> <div style="word-break:break-word; border: 0; mso-border-alt: 0; text-align:left; "> <div style="display: inline-block; border: 0; mso-border-alt: 0; "> <a style="direction:ltr;display:block;text-align:center;margin:0; font-family:Arial, Helvetica, sans-serif; font-size:12px; padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px; color:#000000;font-weight:normal;font-style:normal;text-decoration:none;border-width:2px;border-style:solid;border-color:#000000;background-color:#FFFFFF;border-radius:0px;mso-padding-alt:0;" href="https://go.airfinity.com/e/936853/udy-pitting-weight-loss-drugs-/7r8t7/230032428/h/36skm1JSzUnWnucAQIHUAnsskN7GDb02HSbqZHE023g" target="_blank"><span>Read More →</span></a> </div> </div></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCOWBGIQAXEJAD5HXUA6V5F44D4Y?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><p><span style="line-height:1.5;"><b>Obesity Drugs’ Golden Age: Who Will Benefit?</b></span><br><span style="line-height:1.5;"><b><span style="color:#7f8c8d;"><i>Bloomberg - 28 November 2023</i></span></b></span><br><br><span style="line-height:1.5;">Now that Novo Nordisk and Eli Lilly have developed safe medications that help people lose weight, it’s the beginning of a golden age.</span></p></td> </tr> </tbody> </table></td> </tr> </tbody> <tbody> <tr> <td> <table style="border: 0; width: 100%; border-collapse: collapse; mso-table-lspace:0pt;mso-table-rspace:0pt;" locked="0"> <tbody> <tr> <td style="padding-right: 10px;padding-left: 10px;mso-table-lspace:0pt;mso-table-rspace:0pt;"> <div style="word-break:break-word; border: 0; mso-border-alt: 0; text-align:left; "> <div style="display: inline-block; border: 0; mso-border-alt: 0; "> <a style="direction:ltr;display:block;text-align:center;margin:0; font-family:Arial, Helvetica, sans-serif; font-size:12px; padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px; color:#000000;font-weight:normal;font-style:normal;text-decoration:none;border-width:2px;border-style:solid;border-color:#000000;background-color:#FFFFFF;border-radius:0px;mso-padding-alt:0;" href="https://go.airfinity.com/e/936853/s-like-ozempic-wegovy-mounjaro/7r8tb/230032428/h/36skm1JSzUnWnucAQIHUAnsskN7GDb02HSbqZHE023g" target="_blank"><span>Read More →</span></a> </div> </div></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="padding-top: 10px;" align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MC4MKF4LK7ZBAFHI47EQHISYRLJI?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><font face="Arial, Helvetica, sans-serif"><span style="font-size:20px"><b>Social</b></span></font></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MC4MKF4LK7ZBAFHI47EQHISYRLJI?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="50%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <div class="columnDiv" style="margin-right: 5px;margin-bottom: 5px;"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="padding-bottom: 5px;" align="center"><a href="https://go.airfinity.com/e/936853/-t-YHXe-aQahE8KNSAE8GGphA-s-19/7r8tj/230032428/h/36skm1JSzUnWnucAQIHUAnsskN7GDb02HSbqZHE023g" target="_blank"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCG2N52NU65BDU3O7MGDH5JMRHDE?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="295"></a></td> </tr> </tbody> </table></td> </tr> </tbody> </table> </div></td> <td width="50%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="left"><a href="https://go.airfinity.com/e/936853/-t-RP-dlnsrVYtCdpYCsJHlug-s-19/7r8tm/230032428/h/36skm1JSzUnWnucAQIHUAnsskN7GDb02HSbqZHE023g" target="_blank"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCCBU4SQAN6NCDRJIH7MUCA4WP4A?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="300"></a></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="padding-top: 10px;" align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MC4MKF4LK7ZBAFHI47EQHISYRLJI?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><font face="Arial, Helvetica, sans-serif"><span style="font-size:20px"><b>New Science</b></span></font></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MC4MKF4LK7ZBAFHI47EQHISYRLJI?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><p><span style="line-height:1.5;"><b>Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity</b><br><em>Fatima Quddos et al<br><span style="color:#7f8c8d;">Published: 28 November 2023, Nature Scientific Reports (IF: 4.847)</span></em></span><br><span style="line-height:1.5;"><em>Controlled Study, Not Independent - Peer Reviewed</em></span></p></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="50%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <div class="columnDiv" style="margin-right: 5px;margin-bottom: 5px;"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="border: 0; width: 100%; border-collapse: collapse; mso-table-lspace:0pt;mso-table-rspace:0pt;" locked="0"> <tbody> <tr> <td style="padding-right: 10px;padding-left: 10px;mso-table-lspace:0pt;mso-table-rspace:0pt;"> <div style="word-break:break-word; border: 0; mso-border-alt: 0; text-align:left; "> <div style="display: inline-block; border: 0; mso-border-alt: 0; "> <a style="direction:ltr;display:block;text-align:center;margin:0; font-family:Arial, Helvetica, sans-serif; font-size:12px; padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px; color:#000000;font-weight:normal;font-style:normal;text-decoration:none;border-width:2px;border-style:solid;border-color:#000000;background-color:#FFFFFF;border-radius:0px;mso-padding-alt:0;" href="https://go.airfinity.com/e/936853/articles-s41598-023-48267-2/7r8sf/230032428/h/36skm1JSzUnWnucAQIHUAnsskN7GDb02HSbqZHE023g" target="_blank"><span>View Publication →</span></a> </div> </div></td> </tr> </tbody> </table></td> </tr> </tbody> </table> </div></td> <td width="50%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <div class="columnDiv" style="margin-right: 5px;margin-bottom: 5px;"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="border: 0; width: 100%; border-collapse: collapse; mso-table-lspace:0pt;mso-table-rspace:0pt;" locked="0"> <tbody> <tr> <td style="padding-right: 10px;padding-left: 10px;mso-table-lspace:0pt;mso-table-rspace:0pt;"> <div style="word-break:break-word; border: 0; mso-border-alt: 0; text-align:left; "> <div style="display: inline-block; border: 0; mso-border-alt: 0; "> <a style="direction:ltr;display:block;text-align:center;margin:0; font-family:Arial, Helvetica, sans-serif; font-size:12px; padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px; color:#000000;font-weight:normal;font-style:normal;text-decoration:none;border-width:2px;border-style:solid;border-color:#000000;background-color:#FFFFFF;border-radius:0px;mso-padding-alt:0;" href="https://go.airfinity.com/e/936853/10-1038-s41598-023-48267-2/7r8tq/230032428/h/36skm1JSzUnWnucAQIHUAnsskN7GDb02HSbqZHE023g" target="_blank"><span>DOI →</span></a> </div> </div></td> </tr> </tbody> </table></td> </tr> </tbody> </table> </div></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><span style="font-size:14px;"><span style="line-height:1.5;">Alcohol Use Disorder (AUD) contributes significantly to global mortality. GLP-1 (Glucagon-like peptide-1) and GLP-1/GIP (Glucose-dependent Insulinotropic Polypeptide) agonists, FDA-approved for managing type 2 diabetes and obesity, where the former has shown to effectively reduce the consumption of alcohol in animal models but no reports exist on the latter. In this report, we conducted two studies. In the first study, we conducted an analysis of abundant social media texts. Specifically, a machine-learning based attribution mapping of ~ 68,250 posts related to GLP-1 or GLP-1/GIP agonists on the Reddit platform. Secondly, we recruited participants (n = 153; current alcohol drinkers; BMI ≥ 30) who self-reported either taking Semaglutide (GLP-1 agonist), Tirzepatide (the GLP-1/GIP combination) for ≥ 30 days or, as a control group; no medication to manage diabetes or weight loss for a within and between subject remote study. In the social media study, we report 8 major themes including effects of medications (30%); diabetes (21%); and Weight loss and obesity (19%). Among the alcohol-related posts (n = 1580), 71% were identified as craving reduction, decreased desire to drink, and other negative effects. In the remote study, we observe a significantly lower self-reported intake of alcohol, drinks per drinking episode, binge drinking odds, Alcohol Use Disorders Identification Test (AUDIT) scores, and stimulating, and sedative effects in the Semaglutide or Tirzepatide group when compared to prior to starting medication timepoint (within-subjects) and the control group (between-subjects). In summary, we provide initial real-world evidence of reduced alcohol consumption in people with obesity taking Semaglutide or Tirzepatide medications, suggesting potential efficacy for treatment in AUD comorbid with obesity.</span></span></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCAWYF6INAWZE4ZB7B6IWGSBLIVI?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><p><span style="line-height:1.5;"><span style="font-size:14px;"><i><span style="color:#575756;"><span style="font-family:Arial,Helvetica,sans-serif;">Final optimized clusters. Shown are the final optimized clusters obtained for our sample. <strong>(A)</strong> a scatterplot visualized by the UMAP model, we see the two UMAP components denoted as UMAPx and UMAPy represent the x and y axis of the scatter plot, with different colors to show the different clusters. <strong>(B)</strong> the distribution of posts into each of these clusters with corresponding colors.</span></span></i></span></span></p><p><span style="display: none;"> </span></p></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="padding-bottom: 10px;" align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MC4MKF4LK7ZBAFHI47EQHISYRLJI?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width:100%; border-collapse: collapse; word-break:break-word;" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td align="Center"><img style="width: 100%; display: block; border: none; max-width: 100%; object-fit: fill;" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCWFW4GTIAWBDATANIO5DAYBJILU?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" alt width="600"></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="border: 0; width: 100%; border-collapse: collapse; mso-table-lspace:0pt;mso-table-rspace:0pt;" locked="0"> <tbody> <tr> <td style="padding-top: 10px;padding-right: 10px;padding-bottom: 20px;padding-left: 10px;mso-table-lspace:0pt;mso-table-rspace:0pt;"> <div style="word-break:break-word; border: 0; mso-border-alt: 0; text-align:center; "> <div style="display: inline-block; border: 0; mso-border-alt: 0; width:100%;"> <a style="direction:ltr;display:block;text-align:center;margin:0; font-family:Arial, Helvetica, sans-serif; font-size:12px; padding-top: 10px;padding-right: 20px;padding-bottom: 10px;padding-left: 20px; color:#000000;font-weight:normal;font-style:normal;text-decoration:none;border:0;background-color:#ffed00;border-radius:0px;mso-padding-alt:0;" href="https://go.airfinity.com/e/936853/2023-12-01/7r8s1/230032428/h/36skm1JSzUnWnucAQIHUAnsskN7GDb02HSbqZHE023g" target="_blank"><span>Find out more at airfinity.com</span></a> </div> </div></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 20px;padding-right: 10px;padding-bottom: 10px;padding-left: 10px;"><p><span style="color:#575756;"><span style="font-family:Arial,Helvetica,sans-serif;"><span style="line-height:1.5;"><span style="font-size:9px;">Copyright notice<br> All intellectual property rights in this publication and the information published herein are the exclusive property of Airfinity and may only be used under licence from Airfinity. Without limiting the foregoing, by accessing this publication you agree that you will not copy or reproduce or recirculate or distribute or use any part of its contents in any form or for any purpose whatsoever except under valid licence from Airfinity.<br> Unauthorised distribution is strictly prohibited.</span></span></span></span></p><p><span style="color:#575756;"><span style="font-family:Arial,Helvetica,sans-serif;"><span style="line-height:1.5;"><span style="font-size:9px;">Disclaimer<br> The data and other information published herein are provided on an "as is basis". Airfinity makes no warranties, express or implied, as to the accuracy, adequacy, timeliness, or completeness of the data or fitness for any particular purpose. Airfinity shall not be liable for any loss, claims or damage arising from any party's reliance on the data and disclaim any and all liability relating to or arising out of use of the data to the full extent permissible by law.</span></span></span></span></p></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-bottom: 10px;padding-left: 10px;"><p><span style="font-size:10px;"><span style="font-family:Arial,Helvetica,sans-serif;"><span style="color:#000000;">Want to change how you receive these emails? </span><br><a href=" https://go.airfinity.com/unsubscribeConfirm/936853/542c5aa8b831fd825bcb2b7faf834fe738a139d8de064ec0b66377f887ad3690/230032428 "><span style="color:#000000;">Unsubscribe</span></a><span style="color:#000000;"> from this list or </span><a href=" https://go.airfinity.com/preferences-page?ehash=542c5aa8b831fd825bcb2b7faf834fe738a139d8de064ec0b66377f887ad3690&email_id=230032428&epc_hash=lkW4WF1yEk3ExCcEctcHoa2WgInNToZrRGYy8fiVUxY "><span style="color:#000000;">update</span></a><span style="color:#000000;"> your preferences.</span></span></span></p><p><span style="color:#000000;"><span style="font-size:10px;"><span style="font-family:Arial,Helvetica,sans-serif;">Copyright © 2023 Airfinity Ltd. All rights reserved.</span></span></span></p></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <table class="contentbuilderBaseColumnRow" style="align-items: flex-start; width: 100%; background-color:;" role="presentation" width="100%" cellpadding="0" cellspacing="0"> <tbody> <tr valign="top"> <td width="100%" class="columnCell" style="vertical-align: top;display: inline-block; float:left"> <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; word-break:break-word;"> <tbody> <tr> <td> <table style="width: 100%; border-collapse: collapse; word-break: break-word; font-size: 14px" id="contentRegion" role="presentation" cellspacing="0" cellpadding="0" locked="0"> <tbody> <tr> <td style="font-family: Arial, Helvetica, sans-serif;padding-top: 10px;padding-left: 10px;"><a href="https://go.airfinity.com/e/936853/company-airfinity-ltd-/7r8tt/230032428/h/36skm1JSzUnWnucAQIHUAnsskN7GDb02HSbqZHE023g"><img alt="Linkedin_72" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCM7VFNBUMJFHT7FID6QLWUIAROY?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" title="Linkedin_72"></a> <a href="https://go.airfinity.com/e/936853/Airfinity/7r8tx/230032428/h/36skm1JSzUnWnucAQIHUAnsskN7GDb02HSbqZHE023g"><img alt="Twitter" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCBZRPCK5A75G2XKNITP75ZNVPZQ?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" title="Twitter"></a><br><br><a href="https://go.airfinity.com/e/936853/2023-12-01/7r8s1/230032428/h/36skm1JSzUnWnucAQIHUAnsskN7GDb02HSbqZHE023g"><img alt="Logo_Black_72" src="https://airfinityltd.cdn.salesforce-experience.com/cms/delivery/media/MCRJYJ64VUNJBVVFUFCH7XOJ72XY?oid=00D4L000000igpXUAQ&channelId=0ap4L000000gBKdQAM" title="Logo_Black_72"></a></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table></td> </tr> </tbody> </table> <img alt="" src="https://go.airfinity.com/r/936853/1/230032428/open/1" /><style data-ignore-inlining>@media (prefers-color-scheme: dark) { #_t::before {content:url('https://iqvh3n5b.emltrk.com/v2/iqvh3n5b?rd&d=[UNIQUE]');}} @media (prefers-color-scheme: light) { #_t::before {content:url('https://iqvh3n5b.emltrk.com/v2/iqvh3n5b?rl&d=[UNIQUE]');}} @media print{ #_t {background-image:url('https://iqvh3n5b.emltrk.com/v2/iqvh3n5b?p&d=[UNIQUE]');}} div.OutlookMessageHeader {background-image:url('https://iqvh3n5b.emltrk.com/v2/iqvh3n5b?f&d=[UNIQUE]')} table.moz-email-headers-table {background-image:url('https://iqvh3n5b.emltrk.com/v2/iqvh3n5b?f&d=[UNIQUE]')} blockquote #_t {background-image:url('https://iqvh3n5b.emltrk.com/v2/iqvh3n5b?f&d=[UNIQUE]')} #MailContainerBody #_t {background-image:url('https://iqvh3n5b.emltrk.com/v2/iqvh3n5b?f&d=[UNIQUE]')}</style><div id="_t"></div> <img src="https://iqvh3n5b.emltrk.com/v2/iqvh3n5b?d=[UNIQUE]" width="1" height="1" border="0" alt="" /></body></html>

Get In Touch!

We’ll need a few short details about you and your business.

Get In Touch!

We’ll need a few short details about you and your business.

What our users say?

“The Airfinity report is a guide for world leaders to fix a more ambitious action plan.”

Gordon Brown, WHO Ambassador for Global Health Financing & former UK Prime Minister

“Airfinity has been instrumental in our country's COVID response.”

Head of UK Government
Vaccine Task Force

In a dynamic environment, Airfinity enabled us to remain on track with daily developments to enable more accurate decision-making. Airfinity combines nimbleness of real time data and their group of scientists that can analyse, model and provide strategic analysis for critical decision making.”

Iskra Reic, Executive Vice-President
Astrazeneca

“Probably the most expansive, accurate and helpful of the multiple data sets on an international scale”

Sir John Bell ,
University of Oxford